Serenoa repens, lycopene and selenium vs. tamsulosin for the treatment of (LUTS)/ (BPH): An Italian multicenter comparative randomized study between single or combination therapy

Konpharma (Italy)0 个研究点目标入组 225 人开始时间: 2013年12月11日最近更新: 2017年7月3日

适应症

试验速览

暂无简介。

•1. Age between 55 and 80 years old
•2. Digital rectal examination negative for prostate cancer
•3. Prostate-specific antigen (PSA) = 4 ng / ml, International Prostate Symptom Score (IPSS) = 12, prostate volume = 60 cc (assessed by suprapubic ultrasound), Qmax = 15 ml / s, post -void residual urine <150 ml.

•1. Prostate cancer, previous bladder cancer, diabetes mellitus, neurogenic disorders, severe liver disease, history of orthostatic hypotension or syncope, symptomatic urinary tract infection
•2.Anti-androgens, antidepressants (neuroleptics, anticholinergics) therapy, recent treatment with an a blocker (within 1 month) or phytotherapy including saw palmetto extract (within 3 months), previous medical therapy with 5-ARI or surgical treatment for LUTS/BPH
•3. Patients with catheter or with an episode of acute retention of urine in the last 4 weeks.

发起方

Konpharma (Italy)